Resilience Neuroscience

Resilience Neuroscience is a biotechnology company dedicated to developing a new class of medicines that enhance the brain's natural ability to resist and recover from stress and injury. Founded by Apple Tree Partners (ATP), the company focuses on the biological mechanisms of "resilience" to treat psychiatric and neurological conditions such as PTSD and depression. By targeting specific pathways that promote neural plasticity and emotional regulation, Resilience Neuroscience aims to provide transformative treatments for patients who do not respond to current therapies. The company is currently in the pre-clinical stage, leveraging insights from neuroscience to build a robust pipeline of novel therapeutics. Their approach shifts the focus from merely suppressing symptoms to actively strengthening the brain's inherent protective mechanisms.